Moderna’s stock jumps after biotech raises sales outlook
THE SO WHAT
Moderna guiding up to as much as 25% revenue growth in 2026 reinforces that platform biotechs can re-accelerate once pipelines mature. For operators in adjacent spaces, assume capital will keep flowing to data- and model-heavy drug discovery — partnerships may be easier to strike now than to compete with later.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechTSMC is weighing a move into AI memory chips at Nvidia’s request
If TSMC moves into 3D DRAM at Nvidia’s request, the memory bottleneck in AI shifts from merchant DRAM to vertically coordinated supply between a dominant GPU buyer and the leading foundry. System builders should assume tighter coupling of logic and memory roadmaps—and less pricing slack—over the next node or two.
Deep & Emerging TechPS Logistics subsidiary acquires Tennessee-based trucking business
Regional trucking rollups like PS Logistics buying Roane Transportation are about density and network control in specific lanes. If you depend on fragmented carriers in the Southeast, expect pricing and service terms to consolidate as these networks thicken.
Deep & Emerging TechChip Stocks Roar Back as Strong Data Sink Bonds
Chip stocks ripping higher on macro data underscores how much the AI trade is riding narrative and rates, not just unit demand. If you’re planning multi-year hardware bets, separate market euphoria from actual order books and capacity signals.
Deep & Emerging TechHims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
Hims & Hers locking in a GLP-1 supply deal with Lilly—while agreeing not to compound—shows how access and compliance can be turned into a consumer-health growth story. Digital health players need to secure upstream pharma relationships early if they want to ride the GLP-1 wave.